SpringWorks Therapeutics is working on new potential indications for its IP portfolio while running additional trials. See ...

SpringWorks Therapeutics (SWTX) saw the biggest retail follower increase among biotech stocks last week on Stocktwits, even ...

Our analysis of options history for SpringWorks Therapeutics SWTX revealed 9 unusual trades. Delving into the details, we ...

SpringWorks Therapeutics has a twelve month low of $28.21 and a twelve month high of $62.00. The firm has a market cap of $3.71 billion, a PE ratio of -14.24 and a beta of 0.76.

Financial giants have made a conspicuous bearish move on SpringWorks Therapeutics. Our analysis of options history for SpringWorks Therapeutics (NASDAQ:SWTX) revealed 9 unusual trades. Delving ...

Feb. 20, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a com SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe ...

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare ...

Hard on the heels of the disclosure that Merck KGaA is talking to SpringWorks about a possible takeover, a new FDA approval could have sweetened the deal. Stamford, Connecticut-based SpringWorks ...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Merck & Co... We recently published a list of the 11 Best Pharma Stocks to Buy According ...